American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • American Pharmacy News Reports

Imaging3 contracts Intertek to manage FDA guidance protocols

American Pharmacy News Reports | Jun 25, 2017
Intertek will make sure the Dominion VI product meets quality, health, environmental, safety and social accountability standards.

Imaging3 Inc. has hired Intertek Inc. to oversee hazard analytics and U.S. Federal Drug Administration guidance protocols during the submission of the company’s Dominion VI imaging device with patented SmartScan 3D technology. Read More »

Seattle Genetics submits BLA for lymphoma treatment

Mark Iandolo | Jun 25, 2017
Adcetris treats patients with cutaneous T-cell lymphoma.

Seattle Genetics Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration using data from its recent Phase 3 Alcanza trial and two Phase 2 investigator-sponsored trials of Adcetris. Read More »

Indiana optometrists open ‘Little Eyes’ just for kids

American Pharmacy News Reports | Jun 25, 2017
The owners of

With its identity coined by the founding optometrist’s own child, RevolutionEYES’ “Little Eyes” recently opened in Carmel, Indiana, launching a pediatric eye care clinic caring for youngsters between 6 months and 13 years old. Read More »

Biohaven receives Fast Track Designation for SCA treatment

American Pharmacy News Reports | Jun 25, 2017
Currently, no medications are approved for the treatment of SCA.

Biohaven Pharmaceutical Holding Co. has been granted Fast Track Designation for its product candidate Trigriluzole by the FDA. Read More »

Churchill expands Commercial Leadership Team

American Pharmacy News Reports | Jun 25, 2017
Churchill Pharmaceuticals has expanded its Commercial Leadership Team.

Churchill Pharmaceuticals has expanded its Commercial Leadership Team. Read More »

QuVa Pharma rallies to address antacid shortage

American Pharmacy News Reports | Jun 23, 2017
QuVa Pharma's name derives from “Quality and Innovation.”

Addressing a recently reported nationwide antacid scarcity, QuVa Pharma Inc. — specializing in critical drug shortage products — has rallied with supplies of its own pharmaceutical quality sodium bicarbonate formulation at the ready for U.S. hospital distribution. Read More »

Lannett’s generic influenza drug wins FDA approval

American Pharmacy News Reports | Jun 23, 2017
The product is used to stem infection from some strains of influenza A.

To combat certain types of influenza, Lannett Co. Inc. can now market its Amantadine Hydrochloride Capsules USP in 100 mg. dose form following Food and Drug Administration approval of its Abbreviated New Drug Application. Read More »

Lannett gets FDA approval for extended-release niacin tabs

American Pharmacy News Reports | Jun 23, 2017
The product is available in both 500-mg. and 1000-mg. tablet doses.

Philadelphia-based Lannett Company Inc. recently obtained approval from the U.S. Food and Drug Administration (FDA) for its generic formulation of niacin in extended-release form, with the product available in both 500-mg and 1000-mg tablet doses. Read More »

Amgen presents 19 scientific abstracts to American Headache Society

American Pharmacy News Reports | Jun 23, 2017
Amgen also delivered the results from two Phase 3 studies of the drug.

Amgen recently presented 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society, which took place in Boston. Read More »

OncoSec's melanoma drug receives Orphan Drug Designation

American Pharmacy News Reports | Jun 23, 2017
Tavokinogene telsaplasmid is the active biologic agent in ImmunoPulse IL-12, OncoSec’s lead product candidate.

OncoSec Medical Inc.'s pIL-12 drug, also known as tavokinogene telsaplasmid, has been given an Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »

FDA to review oncology drug from Amgen and Allergan

American Pharmacy News Reports | Jun 22, 2017
In the Phase 3 study analyzing the biosimilar’s performance in treating patients with non-squamous non-small cell lung cancer, the drug met its primary endpoint.

Amgen and Allergan's data supporting their Biologics License Application for ABP 215, a biosimilar candidate to Avastin (bevacizumab), will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration by July 13. Read More »

AbbVie concludes Phase 3 study evaluating rheumatoid arthritis drug

American Pharmacy News Reports | Jun 22, 2017
After 12 weeks of treatment, upadacitinib met the primary endpoints.

AbbVie recently announced positive top-line results from its Phase 3 Select-Next trial, which evaluated upadacitinib as a treatment for rheumatoid arthritis patients. Read More »

SpePham AG to commercialize Navidea's Lymphoseek in Europe

American Pharmacy News Reports | Jun 22, 2017
The drug targets lymph nodes, the most likely place for cancer cells to spread from a primary tumor.

Navidea Biopharmaceuticals Inc. recently announced that SpePharm AG has launched Lymphoseek in the Denmark, the Netherlands and the United Kingdom. Read More »

Cigna, CVS partner to form Cigna HealthWorks

American Pharmacy News Reports | Jun 22, 2017
The program will deliver personalized pharmacy support, contracted discounts at CVS MinuteClinic, and a CVS ExtraCare Health card.

Cigna and CVS Health have launched Cigna HealthWorks, a partnership that brings Cigna benefits to CVS Pharmacy and CVS MinuteClinic retail health care centers. Read More »

Acorda updates tozadenant data at MDS Congress

American Pharmacy News Reports | Jun 22, 2017
Acorda anticipates results from a current Phase 3 clinical trial of the medication in early 2018.

Ardsley, New York-based biopharmaceutical firm Acorda Therapeutics revealed new information derived from clinical and preclinical studies of tozadenant at the recent 2017 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Vancouver, British Columbia. Read More »

Purdue Pharma introduces new packaging for Colace and Senokot

American Pharmacy News Reports | Jun 22, 2017
The new packaging will ship to retailers and wholesalers this year.

Purdue Pharma's Colace product line and Senokot tablets will now come with new packaging. Read More »

Plaintiff lawyer ads may scare some Americans from taking their prescriptions, finds new survey

LocalLabs News Service | Jun 22, 2017

Do television ads by plaintiffs' lawyer firms hawking lawsuits over prescription drugs cause patients to cease taking their prescribed prescriptions? Read More »

Alkermes begins Phase 3b trial for major depressive disorder drug

American Pharmacy News Reports | Jun 20, 2017
The trial will evaluate results from as many as 325 patients over an 11-week period.

Commencing a Phase 3b trial of daily oral medication ALKS 5461, Alkermes PLC will assess the treatment’s feasibility and safety for major depressive disorder patients with insufficient prior results obtained from other drugs. Read More »

Health Affairs Blog reviews issue of surprise medical bills

American Pharmacy News Reports | Jun 19, 2017
Surprise medical bills occur when patients cannot avoid being treated by providers outside their health plan’s contracted network.

The Health Affairs Blog, a vehicle for commentary on health policy and issues affecting the health care industry, recently release an article on surprise medical bills. Read More »

MD Logistics to expand Indiana operations, creating 50 new jobs

American Pharmacy News Reports | Jun 19, 2017
The company, which was founded in Indiana, plans to invest roughly $3.7 million to renovate its Plainfield operations site.

MD Logistics, a third-party logistics company that works with pharmaceutical companies, will expand its Indiana operations, creating 50 new jobs in the process. Read More »

  • «
  • 1
  • 2
  • ...
  • 40
  • 41
  • 42 (current)
  • 43
  • 44
  • ...
  • 168
  • 169
  • »
Trending

Danea Horn, Researcher, University of California

Researcher on 340B: Physicians 'select patients who require more intensive pharmaceutical treatments after joining the 340B program'

Shaun Noorian, CEO of Empower Pharmacy

Empower Pharmacy challenges Eli Lilly tirzepatide patent before U.S. Patent Trial and Appeal Board

David Balto, Former Policy Director at the Federal Trade Commission

Former FTC director on 340B program: ‘Drug discounts are being captured by corporate hospital systems'

Melissa Magstadt, Secretary of Health

South Dakota issues air quality alert due to wildfire smoke

Sally Greenberg, JD, Chief Executive Officer, National Consumers League

National Consumers League announces poll showing support for 340B drug pricing reform

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up